Learn More
BACKGROUND Secukinumab is a fully human anti-interleukin-17A monoclonal antibody. OBJECTIVE Determine the efficacy, safety and usability of secukinumab administered via autoinjector/pen. METHODS This phase III trial randomized subjects with moderate to severe plaque psoriasis to secukinumab 300 mg, 150 mg or placebo self-injection once weekly to Week 4,(More)
  • 1